DD201677A5 - Verfahren zur herstellung von trisubstituierten imidazolderivaten - Google Patents

Verfahren zur herstellung von trisubstituierten imidazolderivaten Download PDF

Info

Publication number
DD201677A5
DD201677A5 DD81232030A DD23203081A DD201677A5 DD 201677 A5 DD201677 A5 DD 201677A5 DD 81232030 A DD81232030 A DD 81232030A DD 23203081 A DD23203081 A DD 23203081A DD 201677 A5 DD201677 A5 DD 201677A5
Authority
DD
German Democratic Republic
Prior art keywords
phenyl
formula
compounds
alkoxy
substituted
Prior art date
Application number
DD81232030A
Other languages
German (de)
English (en)
Inventor
Alfred Sallmann
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of DD201677A5 publication Critical patent/DD201677A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
DD81232030A 1980-07-25 1981-07-23 Verfahren zur herstellung von trisubstituierten imidazolderivaten DD201677A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH571580 1980-07-25

Publications (1)

Publication Number Publication Date
DD201677A5 true DD201677A5 (de) 1983-08-03

Family

ID=4298165

Family Applications (2)

Application Number Title Priority Date Filing Date
DD81232030A DD201677A5 (de) 1980-07-25 1981-07-23 Verfahren zur herstellung von trisubstituierten imidazolderivaten
DD82242110A DD202554A5 (de) 1980-07-25 1982-07-30 Verfahren zur herstellung neuer trisubstituierter oxazolderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DD82242110A DD202554A5 (de) 1980-07-25 1982-07-30 Verfahren zur herstellung neuer trisubstituierter oxazolderivate

Country Status (23)

Country Link
US (1) US4447431A (cs)
EP (1) EP0045081B1 (cs)
JP (1) JPS5756466A (cs)
KR (13) KR850000883B1 (cs)
AR (1) AR230269A1 (cs)
AT (1) ATE17349T1 (cs)
AU (2) AU7340481A (cs)
CA (1) CA1175431A (cs)
DD (2) DD201677A5 (cs)
DE (1) DE3173434D1 (cs)
DK (1) DK331881A (cs)
ES (8) ES8301472A1 (cs)
FI (1) FI812326A7 (cs)
GB (1) GB2080805B (cs)
GR (1) GR75287B (cs)
IE (1) IE52071B1 (cs)
IL (1) IL63410A (cs)
NO (1) NO812542L (cs)
NZ (1) NZ197828A (cs)
PL (8) PL237004A1 (cs)
PT (1) PT73424B (cs)
SU (8) SU1235454A3 (cs)
ZA (1) ZA815078B (cs)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002613A1 (en) * 1981-07-20 1983-08-04 Sallmann, Alfred Trisubstituted oxazo compounds
EP0084756A1 (de) * 1982-01-22 1983-08-03 Ciba-Geigy Ag Trisubstituierte Oxazaverbindungen
FR2633291B1 (fr) * 1988-06-27 1990-09-07 Oreal Derives d'hydroxy-4 isoxazoles, leur procede de preparation et compositions cosmetiques et pharmaceutiques les contenant
US5252322A (en) * 1989-09-22 1993-10-12 The Gillette Company Skin tanning compositions containing imidazoles
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
WO1995013067A1 (en) 1993-11-08 1995-05-18 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
TR199801361T2 (xx) * 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5965583A (en) * 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002509537A (ja) 1997-07-02 2002-03-26 スミスクライン・ビーチャム・コーポレイション 新規なシクロアルキル置換イミダゾール化合物
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
CA2314980A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CN1548436A (zh) * 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (en) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
WO2000025791A1 (en) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
DE60015594T2 (de) 1999-11-22 2005-10-27 Smithkline Beecham P.L.C., Brentford Imidazolderivate und deren verwendung als raf kinase inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ES2241675T3 (es) 1999-11-23 2005-11-01 Smithkline Beecham Corporation Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
JP2003525936A (ja) * 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
MXPA04005880A (es) * 2001-12-18 2004-09-13 Hoffmann La Roche Cis-imidazolinas como inhibidores de la mdm2.
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
KR20060007008A (ko) * 2003-05-08 2006-01-23 아스텔라스세이야쿠 가부시키가이샤 Ｃｏｘ 저해제
MY145281A (en) * 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
JP2008537937A (ja) * 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド［２，３−ｄ］ピリミジン−７−オンおよび３，４−ジヒドロピリミド［４，５−ｄ］ピリミジン−２（１Ｈ）−オン誘導体の製造方法
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558645A (en) * 1968-07-08 1971-01-26 Sandoz Ag 2-(4-(4',5-diphenyl - 2 - imidazolyl)-phenoxy) lower aliphatic monocarboxylic acids
CH561202A5 (cs) * 1971-05-10 1975-04-30 Ciba Geigy Ag
GB1469532A (en) * 1973-06-28 1977-04-06 Dumex Ltd As Imimdazolyl-alkanoic acid derivatives
US4372964A (en) * 1980-10-30 1983-02-08 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols

Also Published As

Publication number Publication date
EP0045081B1 (de) 1986-01-08
KR830006230A (ko) 1983-09-20
KR850002752A (ko) 1985-05-15
ES514584A0 (es) 1983-05-16
IL63410A0 (en) 1981-10-30
ES8306123A1 (es) 1983-05-16
KR850000911B1 (ko) 1985-06-27
SU1235454A3 (ru) 1986-05-30
PL237003A1 (en) 1983-02-28
ES514580A0 (es) 1983-05-16
US4447431A (en) 1984-05-08
NO812542L (no) 1982-01-26
KR850002744A (ko) 1985-05-15
KR850000885B1 (ko) 1985-06-26
KR850002755A (ko) 1985-05-15
KR850000891B1 (ko) 1985-06-26
KR850000883B1 (ko) 1985-06-26
KR850002753A (ko) 1985-05-15
PL232352A1 (cs) 1982-12-20
DD202554A5 (de) 1983-09-21
GB2080805A (en) 1982-02-10
KR850000888B1 (ko) 1985-06-26
ES514579A0 (es) 1983-05-16
KR850000886B1 (ko) 1985-06-26
ES8306119A1 (es) 1983-05-16
ES8306120A1 (es) 1983-05-16
ES8307245A1 (es) 1983-07-01
KR850002750A (ko) 1985-05-15
PL237001A1 (en) 1983-02-28
CA1175431A (en) 1984-10-02
IL63410A (en) 1986-04-29
DK331881A (da) 1982-01-26
GR75287B (cs) 1984-07-13
AR230269A1 (es) 1984-03-01
ATE17349T1 (de) 1986-01-15
KR850002749A (ko) 1985-05-15
ZA815078B (en) 1982-07-28
SU1152520A3 (en) 1985-04-23
AU7340481A (en) 1982-01-28
ES504257A0 (es) 1982-12-01
ES8306124A1 (es) 1983-05-16
ES514582A0 (es) 1983-05-16
PL135822B1 (en) 1985-12-31
PT73424A (en) 1981-08-01
KR850001064B1 (ko) 1985-07-25
SU1138023A3 (ru) 1985-01-30
ES8306121A1 (es) 1983-05-16
AU5655586A (en) 1986-09-11
KR850000889B1 (ko) 1985-06-26
PL236997A1 (en) 1983-01-03
KR850000887B1 (ko) 1985-06-26
SU1227112A3 (ru) 1986-04-23
FI812326L (fi) 1982-01-26
DE3173434D1 (en) 1986-02-20
KR850002748A (ko) 1985-05-15
GB2080805B (en) 1984-03-07
KR850000884B1 (ko) 1985-06-26
JPS5756466A (en) 1982-04-05
KR850002756A (ko) 1985-05-15
ES8301472A1 (es) 1982-12-01
KR850002747A (ko) 1985-05-15
ES514583A0 (es) 1983-05-16
SU1205763A3 (ru) 1986-01-15
PL237005A1 (en) 1983-02-28
ES514581A0 (es) 1983-05-16
IE811680L (en) 1982-01-25
KR850000890B1 (ko) 1985-06-26
PL237000A1 (en) 1983-02-28
PT73424B (en) 1983-06-20
EP0045081A2 (de) 1982-02-03
KR850002754A (ko) 1985-05-15
IE52071B1 (en) 1987-06-10
KR850002745A (ko) 1985-05-15
ES8306122A1 (es) 1983-05-16
PL237002A1 (en) 1983-02-28
KR850000892B1 (ko) 1985-06-26
SU1205764A3 (ru) 1986-01-15
PL237004A1 (en) 1983-02-28
NZ197828A (en) 1985-11-08
SU1169534A3 (ru) 1985-07-23
FI812326A7 (fi) 1982-01-26
KR850002746A (ko) 1985-05-15
KR850000873B1 (ko) 1985-06-22
EP0045081A3 (en) 1982-04-07
ES514585A0 (es) 1983-07-01
SU1145928A3 (ru) 1985-03-15

Similar Documents

Publication Publication Date Title
DD201677A5 (de) Verfahren zur herstellung von trisubstituierten imidazolderivaten
DE69132961T2 (de) Styrylsubstituierte heteroarylverbindungen, welche egf-rezeptor-tyrosinkinase inhibieren
DE2923815C2 (cs)
DE2037610C3 (cs)
DE69118388T2 (de) Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung
DE60003949T2 (de) 5-aryl-1h-1,2,4 triazolverbindungen als cyclooxygenase -2 inhibitoren und dieseenthaltende pharmazeutische zusammensetzungen
DE3434947A1 (de) Isoxazolcarbonsaeure-derivate, ihre herstellung und verwendung
DD232698A5 (de) Verfahren zur herstellung von 2-amino-5-hydroxy-4-methyl-pyrimidin-derivaten
DE69701298T2 (de) Hydroxypyridin-Derivate, ihre Herstellung und ihre pharmazeutische Verwendung
DE2933649A1 (de) Imidazolderivate, sie enthaltende pharmazeutische zusammensetzungen
DE3141198A1 (de) 4,5-polymethylen-4-isothiazolin-3-one, verfahren zu deren herstellung und ihre verwendung als bakterizide und fungizide mittel
DE3443308A1 (de) 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
WO1983002611A1 (en) Trisubstituted diazo compounds
EP0409027A1 (de) Neue Indolderivate, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln
DE3232462A1 (de) 2-nitro-1,1-ethendiamine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE69209099T2 (de) Sulfonamidderivate
DE69302087T2 (de) Trazodone alkyl derivate mit zns wirkung
EP0401798B1 (de) Substituierte Aminoalkylbenzolderivate
DD201788A5 (de) Verfahren zur herstellung neuer diaryl-imidazol-verbindungen
DE2818290A1 (de) Neue naphthyridine
EP0124630A1 (de) Pyrimidin-Thioalkylpyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Arzneimittel
EP0162217A1 (de) 1,2,4-Triazacycloalkadienderivate
DE69000224T2 (de) Thioformamidderivate.
AT374198B (de) Verfahren zur herstellung neuer 2-substituierter mercaptoimidazolderivate, ihrer n-oxyde und ihrer salze
DE69002983T2 (de) Thioformamid-Derivate.